Interleukin-2-inducible T-cell kinase expression and relation to disease severity in systemic lupus erythematosus

被引:9
|
作者
Xu, Wang-Dong [1 ]
Su, Lin-Chong [1 ]
Xie, Qi-Bing [1 ]
Zhao, Yi [1 ]
Liu, Yi [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, 37 Guoxue Xiang, Chengdu 610041, Sichuan, Peoples R China
基金
高等学校博士学科点专项科研基金; 中国国家自然科学基金;
关键词
Lupus; ITK; Th17; Treg; MURINE LUPUS; ITK; RECEPTOR; TH17; DIFFERENTIATION; ANTIBODIES; PREVENT; SUBSET; IL-10; RLK;
D O I
10.1016/j.cca.2016.10.010
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Interleukin-2 inducible T-cell kinase (ITK) is expressed in T cells, and plays an important role in autoimmune inflammatory diseases through regulating the balance of Th17/Treg. However, its role in human systemic lupus erythematosus (SLE) remains unclear. The present study aims to measure the activation status of ITK in T cells from SLE patients and healthy controls, and identify its possible correlation to disease severity. We also discuss the serum levels of Th17, Treg related cytokines including IL-17, IL-21, IL-22, IL-10, analyzing correlation between ITK and Th17/Freg related cytokines. Methods: Peripheral blood samples were drawn from 42 patients with SLE and 43 healthy blood donors, and the phosphorylation of ITK protein was studied in T cells using flow cytometry. In addition, serum levels of Th17/Freg related cytokines were studied with enzyme-linked immunosorbent assay (ELISA). Results: Percentages of CD4(+) pITK(+) T cells, CD8(+) pITK(+) T cells were higher in SLE patients compared with controls, and were positively related to disease activity, some clinical and laboratory parameters. Percentages of CD4(+) pITK(+) T cells, CD8(+)pITK(+) T cells were more prominent in active SLE patients compared with less active patients. Serum levels of Th17 and Treg related cytokines were higher in patients compared with controls. CD4(+)pITK(+) T cells were related to levels of IL-17, IL-21. Conclusion: These data indicate that increased ITK expression could act as a disease activity marker and as a risk factor for involvement in SLE, but it still needs further study to confirm. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 50 条
  • [1] Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders
    Reneau, John C.
    Hwang, Steven R.
    Murga-Zamalloa, Carlos A.
    Buggy, Joseph J.
    Janc, James W.
    Wilcox, Ryan A.
    BLOOD, 2018, 132
  • [2] Interleukin-2-Inducible T-Cell Kinase (ITK) Deficiency - Clinical and Molecular Aspects
    Ghosh, Sujal
    Bienemann, Kirsten
    Boztug, Kaan
    Borkhardt, Arndt
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (08) : 892 - 899
  • [3] Interleukin-2-Inducible T-Cell Kinase (ITK) Deficiency - Clinical and Molecular Aspects
    Sujal Ghosh
    Kirsten Bienemann
    Kaan Boztug
    Arndt Borkhardt
    Journal of Clinical Immunology, 2014, 34 : 892 - 899
  • [4] Multiple Tumors in a Patient with Interleukin-2-Inducible T-Cell Kinase Deficiency: A Case Report
    Di Filippo, Michela
    Tallone, Ramona
    Muraca, Monica
    Pelanconi, Lisa
    Faravelli, Francesca
    Capra, Valeria
    De Marco, Patrizia
    Ognibene, Marzia
    Baldassari, Simona
    Terranova, Paola
    Livellara, Virginia
    Vellone, Valerio Gaetano
    Miano, Maurizio
    Amoroso, Loredana
    Beccaria, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [5] Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors
    Han, Seungil
    Czerwinski, Robert M.
    Caspers, Nicole L.
    Limburg, David C.
    Ding, WeiDong
    Wang, Hong
    Ohren, Jeffrey F.
    Rajamohan, Francis
    McLellan, Thomas J.
    Unwalla, Ray
    Choi, Chulho
    Parikh, Mihir D.
    Seth, Nilufer
    Edmonds, Jason
    Phillips, Chris
    Shakya, Subarna
    Li, Xin
    Spaulding, Vikki
    Hughes, Samantha
    Cook, Andrew
    Robinson, Colin
    Mathias, John P.
    Navratilova, Iva
    Medley, Quintus G.
    Anderson, David R.
    Kurumbail, Ravi G.
    Aulabaugh, Ann
    BIOCHEMICAL JOURNAL, 2014, 460 : 211 - 222
  • [6] Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?
    Ghosh, Sujal
    Drexler, Ingo
    Bhatia, Sanil
    Gennery, Andrew R.
    Borkhardt, Arndt
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [7] Interleukin-2-inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells
    Mamand, Sami
    Carr, Matthew
    Allchin, Rebecca L.
    Ahearne, Matthew J.
    Wagner, Simon D.
    BLOOD ADVANCES, 2019, 3 (05) : 705 - 710
  • [8] Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells
    Mammadli, Mahinbanu
    Harris, Rebecca
    Suo, Liye
    May, Adriana
    Gentile, Teresa
    Waickman, Adam T.
    Bah, Alaji
    August, Avery
    Nurmemmedov, Elmar
    Karimi, Mobin
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (12):
  • [9] Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma
    Mamand, Sarni
    Allchin, Rebecca L.
    Ahearne, Matthew J.
    Wagner, Simon D.
    SCIENTIFIC REPORTS, 2018, 8
  • [10] Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with In Vivo Activity
    Zhou, Danli
    Zuo, Yingying
    Pan, Zhengying
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4979 - 4998